Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More
LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript
LENZ Therapeutics Q1 Earnings Call Highlights
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
LENZ Therapeutics: Speculative But Strong Buy
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week
LENZ Therapeutics (NASDAQ:LENZ) versus Abeona Therapeutics (NASDAQ:ABEO) Critical Comparison
LENZ Therapeutics, Inc. (LENZ) Q4 2025 Earnings Call Transcript
Why Lenz Therapeutics Stock Crashed Today
LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
LENZ Therapeutics, Inc. $LENZ is Ally Bridge Group NY LLC’s 7th Largest Position
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
LENZ Therapeutics to Present at Upcoming Investor Conferences
Calamos Timpani Small Cap Growth Fund Q4 2025 Contributors And Detractors
Analysts Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Target Price at $56.40
New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $56.40 Consensus PT from Brokerages
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
LENZ Therapeutics: Was That A Market Overreaction?
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year Low – Should You Sell?
LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
LENZ Therapeutics to Present at Upcoming Investor Conferences
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $56.40 Average PT from Analysts
LENZ Therapeutics, Inc. (LENZ) Q3 2025 Earnings Call Transcript
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
LENZ Therapeutics, Inc. (LENZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
LENZ Therapeutics, Inc. (LENZ) Upgraded to Buy: What Does It Mean for the Stock?
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
LENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
LENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Citi's Biopharma Back To School Conference Transcript
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia